The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion.
about
Salinomycin as a drug for targeting human cancer stem cellsThe NF-κB Pathway and Cancer Stem CellsThe network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancerCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Redox Regulation in Cancer Stem CellsTargeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressivenessAntioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem CellsTargeting CSC-related miRNAs for cancer therapy by natural agentsHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerGemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cellsNanog1 in NTERA-2 and recombinant NanogP8 from somatic cancer cells adopt multiple protein conformations and migrate at multiple M.W speciesActivin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer.Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment.ABC transporters in CSCs membranes as a novel target for treating tumor relapse.DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer.Epidermal p65/NF-κB signalling is essential for skin carcinogenesisInhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer.Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancersLiposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo.Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancerBmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypesBiological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancerThe role of breast cancer stem cells in metastasis and therapeutic implications.Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.Breast cancer stem cells, cytokine networks, and the tumor microenvironment.Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics.Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cellsSignal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration.NF-κB, stem cells and breast cancer: the links get stronger.CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancerAberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.Development of a Multicolor Bioluminescence Imaging Platform to Simultaneously Investigate Transcription Factor NF-κB Signaling and Apoptosis.Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast CancerOxidized ATM promotes abnormal proliferation of breast CAFs through maintaining intracellular redox homeostasis and activating the PI3K-AKT, MEK-ERK, and Wnt-β-catenin signaling pathways.IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinomaA quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKβDistinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions
P2860
Q21285139-26769F4C-B483-4CCE-BAA8-E615F7E60048Q26750605-F1B09235-99B1-4E9F-A774-98DB403DB917Q26785448-67CDD7E6-9A68-4B48-9BA6-73517DACA576Q26785497-A27D480A-4B50-432B-905C-8C6033DBD13DQ26798198-3F97B18D-3420-4B33-B1DB-87595A4A1F76Q26822776-E25FA7ED-750D-4B68-B0D7-6615CC49F1E4Q26853528-B4D58907-5250-446E-A8DC-A79887544763Q27003230-A3D8331D-443D-4BA3-B11A-5D88D486C5ADQ28085413-2AC9C564-7366-4F57-90DD-08585FC8D9D5Q28297927-465B5B4D-0A05-484B-AD5D-2AF8D45E574EQ28540510-5A48C330-210C-45CA-A97A-14C5F24DD4F7Q30301260-F4E0B346-3CF6-4381-9D2C-CFAF377DAA95Q33572252-380B4172-8B18-4D45-A81A-92A0E24CE6B9Q33879326-4A627E42-4D43-431D-A741-1D923272C8A9Q33894314-A5B6C3F8-EA41-46DB-8C82-4C2370A78BBAQ33991488-DF1CAAE9-9168-4453-9E67-DAC4DE6DBCA7Q34295493-76AD2341-8945-4288-ABC5-2EB4EA375D84Q34357952-AD737916-FCF5-4D5D-A1B8-632D5C3DA858Q34365729-D3884599-9B02-409E-A551-379A5FE04C88Q34442193-76FF63F1-5C4F-4256-9574-223EC36CAC11Q34469657-5D0F5CB2-3C0E-4FDF-838F-F2C0E585D561Q34518047-F0C9D272-17E1-4FDA-A69A-0E22E846EF7AQ34663710-3CD74FB6-DA91-42D6-B63A-7A2E5491A33EQ35070157-0299022E-B715-4F11-8318-0EDB213BA39EQ35181463-E899EBCA-FCEE-40C3-B8CC-CFDB26570139Q35571904-CD5A1651-C9BE-497A-9750-DABDAF1DADE5Q35585820-B017447E-7788-45F6-9B49-DF12CAC2CAEEQ35586803-238A4A94-B41F-4C67-9EA6-9114C53DD23CQ35604202-150005C0-85AC-4CFA-B33C-6D8E0BA5519AQ35608668-284673AF-2E47-4D24-B6FC-E8FC3D28E2CBQ35781581-70FA56A9-FD20-46BE-ACCD-B7A5D0713C4CQ35794436-08A7F4EE-54A1-404F-B475-1A92BE995666Q35966191-F81356C7-224A-4CB1-9F3B-D774C7271950Q36079521-74A04EF5-9AAE-48BE-A5BF-B112632D53EBQ36169303-0AD8B07E-C08B-48A5-90D0-26EC40186624Q36189543-3C802383-DA4D-4ABA-89D9-77E3C944069CQ36266768-F87BD734-F579-454C-88AC-52D0FD45B223Q36348701-A5D6B867-2E3A-4954-A87E-6A6A6F4B36F4Q36395993-917C645E-3476-4245-B03D-C49A86E47CF8Q36544675-86454C1C-29DF-4BCB-95B2-4785E01840F8
P2860
The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@ast
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@en
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@nl
type
label
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@ast
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@en
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@nl
prefLabel
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@ast
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@en
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@nl
P2093
P2860
P1433
P1476
The canonical NF-kappaB pathwa ...... and tumor stem cell expansion.
@en
P2093
Andrew A Quong
Christopher Albanese
David Joyce
John Ojeifo
L Andrew Shirley
Manran Liu
Mathew C Casimiro
Nicole E Willmarth
Richard G Pestell
Sanjay Katiyar
P2860
P304
10464-10473
P356
10.1158/0008-5472.CAN-10-0732
P407
P577
2010-12-01T00:00:00Z